Akèy › Myelom Miltip › Nebraska › Omaha
Etid klinik pou Myelom Miltip nan Omaha, NE
16 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Omaha (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Nebraska Cancer Specialists, Omaha
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- University of Nebraska Medical Center, Omaha
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Nebraska Cancer Institute, Omaha
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Ap rekrite
- University of Nebraska Medical Center, Omaha
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Ap rekriteFaz 1
- University of Nebraska, Omaha
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- University of Nebraska Medical Center, Omaha
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Ap rekrite
- Unversity of Nebraska Medical Center, Omaha
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- University Of Nebraska Medical Center, Omaha
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
Halt Aging in Survivors of Blood Cancers
Ap rekrite
- University of Nebraska Medical Center, Omaha
Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- ak 1 plis
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
- ak 1 plis
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Ap rekriteFaz 2
- Nebraska Cancer Specialists, Omaha
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO26 etid
- Columbus, OH24 etid
- Rochester, MN24 etid
- Baldwin Park, CA23 etid
- St. Louis, MO23 etid
- Washington, DC22 etid
Lòt etid nan Omaha
- Kansè pwostat28 etid
- Kansè Poumon ki pa ti selil25 etid
- Kansè nan tete23 etid
- Kansè (tout kalite)19 etid
- Kansè kolorektal19 etid
- Kansè ovè15 etid
- Kansè pankreyas14 etid
- Kansè Metastatik14 etid
- Limfòm Non-Hodgkin14 etid
- Ensifizyans kadyak13 etid
- Kansè poumon13 etid
- Karsinòm selil skuamèz tèt ak kou13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.